MDxHealth (MDxHealth) ROCE % : -24.87% (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is MDxHealth ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MDxHealth's annualized ROCE % for the quarter that ended in Mar. 2024 was -24.87%.

MDxHealth ROCE % Historical Data

The historical data trend for MDxHealth's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MDxHealth ROCE % Chart

MDxHealth Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-102.52

-111.40

-70.03

-51.92

-35.65

MDxHealth Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-29.94	-37.11	-16.73	-58.27	-24.87

MDxHealth ROCE % Calculation

MDxHealth's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-37.517	/	( ( (119.135 - 18.278)	+	(129.132 - 19.523) )	/ 2 )
	=	-37.517	/	( (100.857	+	109.609)	/ 2 )
	=	-37.517	/	105.233
	=	-35.65 %

MDxHealth's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-26.416	/	( ( (129.132 - 19.523)	+	(121.745 - 18.95) )	/ 2 )
	=	-26.416	/	( ( 109.609	+	102.795 )	/ 2 )
	=	-26.416	/	106.202
	=	-24.87 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

MDxHealth (NAS:MDXH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MDxHealth ROCE % Related Terms

Thank you for viewing the detailed overview of MDxHealth's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

MDxHealth (MDxHealth) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » ROCE %

Comparable Companies

BIOQ PSNL VNRX PRE ENZ PRPH ACRS BNR DRIO AWH TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

N/A

Address

Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040

Website

https://www.mdxhealth.com

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.